Abstract 590P
Background
Colorectal cancer (CRC) CRC with peritoneal metastasis (PM) obtain poor prognosis. Peritoneal Cancer Index (PCI) is used to evaluate the PM extent and selection of Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). However, PCI score assessed before surgery is not precise.We have developed a novel AI framework of DeAF (Decoupling feature alignment and fusion) to aid the selection and predict completeness of CRS in PM.
Methods
185 CRC patients with PM recruited from four tertiary hospitals were enrolled. The internal patient cohort was subsequently stratified into training and validation cohorts, comprising 84 and 30 individuals, respectively. Deep learning was used to train the DeAF model of Simsam algorithms by contrast CT images and then cooperate with clinicopathological parameters to increase the performance. The performance was evaluated by accuracy, sensitivity, specificity, and AUC by ROC in the internal and external validation cohorts.
Results
The AI model demonstrated a robust ability to predict the completeness of CRS with AUC of 0.9 in internal validation cohort. The model can predict whether patients are suitable for CRS. It can differentiate patients who would benefit from CRS. The model also showed high predictive performance of CRS completeness in external validation cohorts with AUC values of 0.906, 0.960, and 0.933, respectively (rounded to three decimal places).
Conclusions
The novel DeAF framework can aid surgeons to select proper patients for CRS and predict the completeness of CRS. The model can change surgical decision-making and provide potential benefits for patients with PM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16